Processing

Please wait...

Settings

Settings

Goto Application

1. AU2002212471 - Peptides for use in the treatment of alzheimer's disease

Office
Australia
Application Number 2002212471
Application Date 01.11.2001
Publication Number 2002212471
Publication Date 21.02.2002
Publication Kind A
IPC
C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Applicants Insight Biotechnology Limited
Inventors Milton, Nathaniel Gavin Nicolas
Priority Data 0026738.5 01.11.2000 GB
0026739.3 01.11.2000 GB
Title
(EN) Peptides for use in the treatment of alzheimer's disease
Abstract
(EN) Anti-sense peptides that correspond to Amyloid-ß protein residues 1-43 are identified, and are used to identify protein binding sites on enzymes that interact with Amyloid-ß. The anti-sense peptides can be used as, or to identify, therapeutic agents that prevent Amyloid-ß cytotoxicity, and may be useful in the treatment of Alzheimer's disease. The anti-sense peptides show sequence similarity to the protein kinase cdc2, and it has now been found that the cytotoxic form of Aß is phosphorylated.
Related patent documents